Pseudopeptide ligands for MHC II-restricted T cells

被引:19
作者
Cotton, J [1 ]
Hervé, M [1 ]
Pouvelle, S [1 ]
Maillère, B [1 ]
Ménez, A [1 ]
机构
[1] CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France
关键词
amide bond reduction; I-E-d; MHC II molecule; N-methylation; pseudopeptides; T cell hybridoma;
D O I
10.1093/intimm/10.2.159
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The potential therapeutic use of peptides to activate or anergize specific T cells is seriously limited by their susceptibility to proteolytic degradation, Classically, peptides are stabilized by incorporation of non-natural modifications including main chain modifications, In the case of MHC Ii-restricted peptides, the peptide backbone actively participates to the interaction with the MHC molecule and hence may preclude the peptidomimetic approach, We thus investigated whether a single amide bond modification influenced the peptide capacity to bind to a MHC II molecule and to stimulate specific T cells, Twenty pseudopeptide analogs of the I-E-d binder 24-36 peptide, whose sequence was derived from a snake neurotoxin, were obtained by replacing each amide bond of the peptide central part, by either a reduced psi[CH2-NH] or N-methylated psi[CO-NMe] peptide bond, In agreement with the major interacting role played by the peptide backbone, several peptides displayed a low, if any, capacity to bind to the MHC II molecule and did not lead to T cell stimulation, However, one-third of the peptides were almost as active as the 24-36 peptide in I-E-d binding assays and one-fifth in T cell stimulation assays, Among them, two pseudopeptides displayed native-like activity, Good binders were not necessarily good at stimulating T cells, demonstrating that main chain modification also affected T cell recognition, We thus showed that a peptidomimetic approach could create a new type of MHC II ligand to control T cell responses.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 49 条
[1]   DEVELOPMENT OF HIGH POTENCY UNIVERSAL DR-RESTRICTED HELPER EPITOPES BY MODIFICATION OF HIGH-AFFINITY DR-BLOCKING PEPTIDES [J].
ALEXANDER, J ;
SIDNEY, J ;
SOUTHWOOD, S ;
RUPPERT, J ;
OSEROFF, C ;
MAEWAL, A ;
SNOKE, K ;
SERRA, HM ;
KUBO, RT ;
SETTE, A ;
GREY, HM .
IMMUNITY, 1994, 1 (09) :751-761
[2]   KINETIC INTERMEDIATES IN THE REACTIONS BETWEEN PEPTIDES AND PROTEINS OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II [J].
BEESON, C ;
MCCONNELL, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :8842-8845
[3]   MINIMUM LENGTH OF AN IDIOTYPIC PEPTIDE AND A MODEL FOR ITS BINDING TO A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULE [J].
BOGEN, B ;
LAMBRIS, JD .
EMBO JOURNAL, 1989, 8 (07) :1947-1952
[4]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[5]  
BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687
[6]   BROP - A NEW REAGENT FOR COUPLING N-METHYLATED AMINO-ACIDS [J].
COSTE, J ;
DUFOUR, MN ;
PANTALONI, A ;
CASTRO, B .
TETRAHEDRON LETTERS, 1990, 31 (05) :669-672
[7]  
Ertl HCJ, 1996, J IMMUNOL, V156, P3579
[8]  
FAUCHERE JL, 1992, ADV DRUG RES, V23, P127
[9]  
FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676
[10]   T-CELL RECEPTOR ANTAGONIST PEPTIDES ARE HIGHLY EFFECTIVE INHIBITORS OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS [J].
FRANCO, A ;
SOUTHWOOD, S ;
ARRHENIUS, T ;
KUCHROO, VK ;
GREY, HM ;
SETTE, A ;
ISHIOKA, GY .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (04) :940-946